Related Experiment Video
Updated: May 2, 2026
Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
Published on: February 16, 2015
Novel approaches and mechanisms of immunotherapy for glioblastoma
Meenakshi Hegde1, Kevin J Bielamowicz, Nabil Ahmed
1Center for Cell and Gene Therapy; Texas Children's Cancer Center; Department of Pediatrics, Baylor College of Medicine; Houston, TX 77030, USA.
Abstract:
Glioblastoma (GBM) is the most aggressive primary brain tumor. Combination therapy with surgery, radiation, and chemotherapy is not curative at present and carries a significant risk of toxicity. Advancements in the knowledge of tumor biology and tumor microenvironment have led to the development of novel targeted therapies for glioblastoma. In the past 15 years, a vast amount of pre-clinical data has been generated for glioblastoma immunotherapy. Translating these promising results into the clinic is, however, still an evolving process. Early clinical trials have demonstrated the feasibility and safety of several such approaches in patients with recurrent as well as newly diagnosed glioblastoma. Both passive as well as active immunotherapeutic modalities have also shown potential clinical benefit in at least a subset of these patients. This brief review discusses 'why' and 'how' various types of immunotherapies are being employed to treat glioblastoma.
Insights
Glioblastoma immunotherapy shows promise for treating this aggressive brain cancer. Early trials indicate safety and potential clinical benefit, advancing treatment options beyond traditional therapies.
Area of Science:
- Neuro-oncology
- Immunology
- Cancer Therapy
Background:
- Glioblastoma (GBM) is an aggressive primary brain tumor with limited curative options.
- Current treatments (surgery, radiation, chemotherapy) carry significant toxicity risks.
- Advances in understanding GBM biology and microenvironment drive novel therapeutic development.
Purpose of the Study:
- To review the rationale ('why') and methodologies ('how') of glioblastoma immunotherapy.
- To discuss the translation of preclinical immunotherapy data into clinical applications.
- To highlight the evolving landscape of targeted therapies for GBM.
Main Methods:
- Review of preclinical data on glioblastoma immunotherapy over the past 15 years.
- Analysis of early clinical trial results for safety and feasibility.
- Discussion of passive and active immunotherapeutic modalities.
Main Results:
- Extensive preclinical data supports glioblastoma immunotherapy.
- Early clinical trials demonstrate feasibility and safety in recurrent and newly diagnosed GBM.
- Both passive and active immunotherapies show potential clinical benefit in subsets of patients.
Conclusions:
- Immunotherapy represents a promising avenue for glioblastoma treatment.
- Clinical translation of immunotherapy is an ongoing and evolving process.
- Further research and clinical trials are essential to optimize immunotherapy for GBM patients.
